The expression of the p53 tumor suppressor protein is frequently increased in a great variety of human cancers, making this antigen an attractive candidate for targeting therapeutic T cell immunity. However, potential complications as a result of immunological tolerance or auto-immune pathology must be taken into account when exploiting this ubiquitously expressed auto-antigen for immunotherapy of cancer.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.